Staurosporine, a potent protein kinase C (PKC) inhibitor, was studied for its effects on 
INTRODUCTION
Protein kinase C (PKC) is a family of enzymes that play a crucial role in signal transduction and other cellular processes [1, 2] . PKC is activated by diacyglycerol (DAG), phospholipids and Ca2+. A group of Ca2+-insensitive PKC isoenzymes has also been characterized [3, 4] . Tumour-promoting phorbol esters bind to and activate PKCs [5, 6] . Pharmacological studies of cellular responses mediated by phorbol esters have shown that these agents operate through specific receptors that can be measured by using 3H-labelled phorbol 12,1 3-dibutyrate (PDBu) or phorbol myristate acetate [7] [8] [9] . One characteristic of PKC activation in stimulated cells is the subcellular redistribution of PKC, in which the soluble form of the enzyme is converted into a particulate form [10, 11] . In human polymorphonuclear leucocytes (PMNs), translocation of PKC correlates with PMN stimulation by phorbol esters [11] . PKC antagonists (e.g. sphinganine and sphingosine) which interfere with DAG binding to the regulatory domain inhibit the adhesion of PKC to the particulate fraction [12] and depress PMN stimulation [13] [14] [15] . Unlike sphingosine, staurosporine, a potent PKC inhibitor that interacts with the catalytic domain of PKC [16] , induces contrasting effects in many cell types. In PMN, for example, staurosporine both inhibits [17, 18] and potentiates the chemoattractant-mediated respiratory burst [19, 20] and promotes exocytosis [18] . Although staurosporine does not affect the binding of phospholipid and whereas PKC histone-phosphorylating activity of both fractions was almost completely inhibited. Incubation of staurosporinepretreated particulate fractions with soluble fractions enriched the particulate fraction in PDBu-binding sites at the expense of the soluble fraction, without altering the binding affinity of PDBu for either fraction. Stimulation of PMNs with chemotactic N-formyl peptides induced a transient increase in PDBu binding. This effect was potentiated by approx. 520 by staurosporine. These results show that, in addition to its interference with PKC protein-phosphorylating activity, staurosporine enhances both PDBu-binding capacity and affinity to PMNs, through a mechanism involving Ca2l-dependent and -independent processes. Alterations of PDBu binding to soluble and particulate fractions suggest that the enhanced binding capacity in intact PMNs may be due to translocation of PDBu receptors, presumably PKC units. This phenomenon may affect PKCdependent cellular responses mediated by physiological stimulation.
phorbol ester to PKC in cell-free systems [21] , it was recently shown to alter PDBu binding to intact platelets [22] . To gain insight into the mechanism of staurosporine action in PMNs solution which contained an equimolar amount of fatty-acid-free BSA.
Isolation of PMNs
Heparinized human venous blood from healthy volunteers was centrifuged over a cushion of mixture of a Ficoll and Hypaque (Monopoly Resolving Medium), as described elsewhere [23, 24] . The purified PMNs (97 %) were subjected to hypotonic lysis, washed, resuspended in Hanks balanced salt solution (HBSS) and maintained at 4°C until use.
Stimulation of PMNs and preparation of subcellular fractions Neutrophils (40 x 106/20 ml) were prewarmed for 5 min at 37°C and treated for 15 min with staurosporine at the indicated concentrations. Cells were then diluted with 25 ml of ice-cold HBSS and collected by centrifugation at 400 g for 10 min at 4 'C. Pellets were resuspended in the lysis buffer containing 20 mM Tris/HCI, pH 7.5, 0.25 M sucrose, 2 mM phenylmethanesulphonyl fluoride, 0.01 % leupeptin, 50 mM 2-mercaptoethanol and, as indicated, 2 mM EDTA and 5 mM EGTA. The cells were then disrupted by sonication at 25 W (four 10 s bursts) with a Fisher model 20/200 SV TC4C instrument. Post-nuclear supernatants were centrifuged at 100000 g for 60 min in a Beckman TLIOO centrifuge and the soluble fraction was separated from the pellets (particulate fraction). The particulate fraction was resuspended in 250 1l of lysis buffer containing 0.1 0% Triton X-100, homogenized by sonication (two 10 s bursts) at 4 'C and then incubated in an ice bath for 30 min.
[3H]PDBu binding to PMNs
PDBu binding was performed as described previously [25] . Briefly, batches of 5 x 106 PMNs in 1 ml of HBSS containing 0.1 0% BSA were pretreated at 37 'C for various periods of time in the absence (control) or presence of staurosporine at the indicated concentrations and then incubated for 5 min with 1 nM [3H]-PDBu, in the absence or presence of 1 ,uM unlabelled PDBu to estimate non-specific binding. Cells were rapidly diluted with 3 ml of ice-cold 0.5 % DMSO and harvested on Whatman GF-B filters which had been soaked in fresh 0.3 % polyethylenimine solution for 1 h before use [26] . The filters were then washed with 3 x 3 ml of ice-cold 0.50% DMSO and suspended in 4 ml of Hionic Fluor for radioactivity measurements. Specific binding was calculated as the difference between total and non-specific binding. PDBu-binding parameters (Kd and Bmax ) were determined at equilibrium by incubating control and staurosporinetreated PMNs with concentrations of [3H]PDBu from 0.25 to 50 nM for 20 min (37 'C) or for 2 h (4°C). In some experiments, PMNs were depleted of Ca2+ as described elsewhere [27] , then incubated in Ca2+-free HBSS in the presence of 1 ,uM Fura 2 AM [24] . They were then washed and resuspended in HBSS containing 1 mM EGTA and treated with staurosporine. Binding data were analysed by using the LIGAND program developed by Munson and Rodbard [28] .
[3H]PDBu binding to particulate and soluble fractions The incubation mixture (250 1l), containing 20 Whatman GF-C filters and washed three times as described above [26] . Maximal non-specific binding represented approx. 25 % of total binding.
Assay of PKC activity
The particulate fraction was centrifuged at 100000 g for 30 min at 4°C and the supernatant, referred to below as the particulate elutable fraction, was collected. The pellets were suspended in 2501ul of lysis buffer containing 0.1 % Triton X-100 and homogenized by sonication. This latter fraction is referred to as the non-elutable particulate fraction. PKC activity was assayed by measuring the incorporation of 32P into histone [11] . Briefly, the reaction mixture contained 10 mM MgCl2, 1 mM CaCl2, 2 ,tg of phosphatidylserine, 0.1 ,ug of 1,2-sn-diolein, 20 ,tg of histone, 10 ,uM ATP (containing 0.5 ,uCi of [32P]ATP) and 2 ,ug of soluble or elutable protein in 100 4u1 of 20 mM Tris/HCI, pH 7.5. Reactions were started with ATP, allowed to run for 10 min at 30°C and stopped by addition of 400 ,ul of ice-cold 20 % trichloroacetic acid followed by 100 #1 of BSA (2.5 mg/ml) as carrier. Precipitates were collected by centrifugation at 10000 g for 10 min and washed twice after dissolution of the pellet in 0.5 M NaOH. The pellets were dissolved in 0.5 M NaOH and mixed with 4 ml of Hionic fluor for radioactivity measurement. PKC activity was expressed in pmol of 32p incorporated/min per mg of protein and was calculated by subtracting the activity measured in the absence of Ca2", phosphatidylserine and diolein from that measured in their presence. No significant PKC activity could be measured in the non-elutable particulate fraction, and the PKC activity of the particulate fraction is therefore that found in the elutable fraction. and mixed with 4 ml of Hionic fluor for radioactivity measurement. For analysis of staurosporine distribution in PMNs, pellets were resuspended in HBSS and sonicated at 25 W (2 x 10 s). The sonicated preparations were centrifuged for 30 min at 100000 g at 4°C and the supernatants were drawn off. The pellets were finally resuspended in HBSS containing 0.1 % Triton X-100 and homogenized by sonication.
Statistical analysis
Values are gives as means + S.E.M. of at least three experiments run in duplicate. Statistically significant differences between experiments were identified by Student's paired t test. Table 2 ). equivalent respectively (Table 2) . PMN treatment with 100 nM and 500 nM staurosporine enhanced the number of particle- [29] . To examine whether staurosporine alters the physiological stimulation of the PDBubinding redistribution, PMNs were treated with 100 nM staurosporine and challenged with 100 nM fMLP. Results in Figure 5 confirm that fMLP induced a transient increase in PDBu binding, which reached a peak at 30 s and returned to baseline by 4 enhanced the maximal fMLP-induced response by approx. 52 % but inhibited the return to basal level.
RESULTS

Staurosporine increased
DISCUSSION
The conversion of soluble PKC into its particulate form (translocation) in stimulated cells is considered as a prerequisite for PKC activation by intravesicular DAG. Physiological stimuli promote transient and reversible PKC redistribution, whereas non-physiological stimuli such as phorbol esters induce tight PKC association to the membrane [11, 29, 31, 32] . PKC binds to the plasma membrane via the regulatory PKC domain and is inhibited by competitive inhibitors of DAG binding such as sphinganine [12] and dioctanoylglycerol [33] . In the present study, we have analysed the effect of PMN treatment by staurosporine on the kinetic parameters of PDBu-binding sites, which, on the basis of the known specificity of phorbol esters, are assumed to be PKC [5, 6, 14, 25, 29] . Results show that staurosporine enhanced both binding capacity and PDBu affinity for PMNs. This effect appears to be due to translocation of PDBubinding sites. This was first suggested by the rapid and marked increase in specific PDBu binding to the PMN surface after treatment at 37°C, but not at 4°C (Figure 1 ). Analysis of this event at binding equilibrium ( [34] . PDBu-binding capacity to particulate fractions of PMN treated with 100 nM and 500 nM staurosporine was increased by approx. 40000 and 94000 sites respectively, whereas there was a loss of 295000 and 343000 sites respectively from the soluble fraction (Table 2 ). In the subcellular model of translocation of PDBu-binding sites approx. 33000 sites were gained by the particulate fraction, whereas about 75 000 sites disappeared from the cytosol. One possible explanation for this overall loss of PDBu-binding sites is that some translocated PKC molecules may bind to the particulate fraction via the DAG-binding site and thus become inaccessible to PDBu, as indicated by the inhibitory effect of sphinganine on PKC adhesion to vesicles [12] . Alternatively, it may have been due to proteolysis [11, 35] .
The mechanism by which staurosporine enhances the redistribution of PDBu-binding sites is not known. Both direct and indirect effects may be involved. Indirect effects may occur through factors known to facilitate PKC translocation, such as DAG and acidic phospholipids [12, 36] or Ca2l [27, 29] . In human PMNs, the breakdown of phosphatidylcholine through the phospholipase D pathway provides a major source of phosphatidic acid and DAGs [37, 38] , and treatment of PMNs with staurosporine enhances fMLP-mediated activation [39] . We confirmed this finding (results not shown) and found that treatment of PMNs for 15 min with 0.1, 0.5 or 1 ,uM staurosporine itself increased the basal level of phosphatidic acid by respectively 114, 200 and 212 % relative to control values, suggesting that phosphatidic acid or its metabolites (i.e. lysophosphatidic acid or DG) may be potential candidates for the PDBu-binding-site translocation. Alteration in cytosolic Ca2l has also been involved in PKC translocation mediated by chemoattractants such as fMLP [27, 29] . Unlike fMLP, staurosporine failed to induce marked alterations in Ca2+-levels under our conditions [24] , whereas an increase in cytosolic Ca2+ concentration has been reported [40] . A role of Ca2+ is further supported by our observation that the Ca2+ depletion of PMNs inhibited approx. 40 % of the increase in Bmax values (Table 4 ). These data suggest that both Ca2+-dependent and -independent processes may be involved in PDBu-binding-site redistribution. By contrast, Ca2+ depletion failed to alter the enhancement of PDBu binding affinity induced by staurosporine (Table 4 ). In platelets, staurosporine was found to increase PDBu-binding affinity through a Ca2+-dependent process [22] , but failed to alter PDBu-binding capacity. These differences between platelets and PMNs may be due to cell selectivity, but could also be explained by differences in the experimental conditions. Alternatively, staurosporine may enhance PDBu-binding capacity through a direct effect. This is suggested by its ability to interact with ATPbinding sites on PKC [21] . Such an interaction may occur between membrane-associated staurosporine and soluble PKC and thus facilitate the adhesion of the latter to the particulate fraction.
The redistribution of PDBu-binding sites mediated by staurosporine was associated with a strong decrease in the PKC histone-phosphorylating activity of the particulate fraction (Figure 3 ). Staurosporine has also been reported to inhibit the phosphorylation of some proteins in vivo [18, 41] , including the 47 kDa species, implicated in the PMN respiratory-burst response to phorbol 12-myristate 13-acetate (PMA) and chemoattractants. Although inhibition of protein phosphorylation is generally associated with a depressed respiratory burst in PMAstimulated PMNs, the use of staurosporine under certain conditions has dissociated the inhibition of the phosphorylation of the 47 kDa species from the fMLP-induced PMN respiratory burst [41] . It was suggested that PMNs may use a simulatory pathway involving a kinase distinct from that which is activated by phorbol ester [41] . We previously showed that staurosporine enhanced the chemoattractant-induced respiratory burst under certain conditions in which that induced by PMA was depressed [19] . This finding is compatible with the above hypothesis and confirms the utility of staurosporine is dissociating signaltransduction pathways [41] . We show here that staurosporine also potentiated the transient redistribution of PDBu binding in PMNs stimulated by fMLP, resulting in the persistence of PDBubinding sites at the surface of PMNs ( Figure 5 ). Whether this effect is related to enhancement of the fMLP-stimulated respiratory burst [19] remains to be examined. Staurosporine has also been reported to have other several activating effects. In PMNs, it promotes actin polymerization [42] and induces a prolonged release ofcomponents of secretory vesicles and specific granules, with a time course and pattern of activity similar to those induced by PMA [18] . Staurosporine-mediated exocytosis, like PKC translocation (Table 4) , occurred in Ca2l-depleted PMNs. These similarities suggest the existence of a common pathway leading to exocytosis and PKC translocation. In platelets, staurosporine potentiates PDBu-binding-site translocation induced by thrombin [22] and promotes marked thrombinmediated accumulation of inositol phosphates [43] . In other cell types, staurosporine promotes changes in morphology and differentiation similar to those induced by phorbol ester [44] and mimics nerve growth factor for the induction of neuropeptide gene expression [45] . Whether or not these stimulating and priming properties of staurosporine are related to the metabolic consequences of PKC redistribution remains to be determined. In conclusion, staurosporine promotes the expression of PDBubinding sites, through the enhancement of both PDBu affinity (K) and total binding capacity (Bmax). The latter effect is associated with redistribution of PDBu-binding sites between the soluble and the particulate compartment; this occurs with no apparent change in cytosolic Ca2l levels, but appears to be mediated by both Ca2l-dependent and -independent processes. Staurosporine may thus provide an additional tool for investigating the mechanism of PKC translocation. However, the fact that it increases the affinity of ligands to PKC regulatory units in intact cells, but not in cell-free systems, will complicate its use as a pharmacological probe for PKC.
